brand logo

Am Fam Physician. 2020;102(11):694

Clinical Question

Can drug treatments improve outcomes in people with dementia?

Bottom Line

Some treatments can improve cognition on research scales, but daily function will not be affected in a noticeable way. Managing behavioral or psychological issues with medication is not supported by current evidence. (Level of Evidence = 1a)

Synopsis

The authors searched four databases, including the Cochrane Library, a clinical trials database, and bibliographies of other systematic reviews, to identify all English-language studies of drug treatments for cognition, function, or behavioral and psychological symptoms associated with Alzheimer-type dementia. Two authors screened possible articles for inclusion. One author performed data extraction, which was verified by a second author. The authors assessed risk of bias and only analyzed results from studies with low or medium risk, removing 97 of the 163 unique studies they identified. The researchers found a small improvement in cognition (standardized mean difference = 0.30) with a low strength of evidence for cholinesterase inhibitors, although there was no effect on overall function or global clinical impression. The most frequently studied cholinesterase inhibitor was donepezil (Aricept). In patients with moderate to severe disease, adding memantine (Namenda) to a cholinesterase inhibitor improved cognition and overall clinical impression, but not function compared with placebo. No treatments had sufficient evidence of their benefit on behavioral or psychological symptoms. Withdrawal from treatment because of adverse effects was higher with cholinesterase inhibitors galantamine (Razadyne) and rivastigmine (Exelon) compared with placebo. There was not significant heterogeneity among the studies. The likelihood of publication bias was not reported.

Study design: Meta-analysis (randomized controlled trials)

Funding source: Government

Setting: Various (meta-analysis)

Reference:FinkHALinskensEJMacDonaldRet alBenefits and harms of prescription drugs and supplements for treatment of clinical Alzheimer-type dementia. Ann Intern Med2020;172(10):656–668.

Editor's Note: Dr. Shaughnessy is an assistant medical editor for AFP.

Already a member/subscriber?  Log In

Subscribe

From $145
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available

Article Only

$25.95
  • Immediate, unlimited access to just this article
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

Continue Reading

More in AFP

More in Pubmed

Copyright © 2020 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.